Title: 0819 - Validity of Soprolife® Camera in Carious Lesion Activity Assessment
Sophie Doméjean (Presenter)
Unversité Clermont Auvergne
Noémie Drancourt, Unversité Clermont Auvergne
Bruno Pereira, University Hospital Clermont-Ferrand
Valérie Roger-Leroi, Unversité Clermont Auvergne
Objectives: It is now commonly accepted that caries diagnostic at the lesion level encompasses, beside the detection (presence/absence) and the severity assessment (depth and cavitation), the activity assessment (active/inactive). Several concepts/tools have been described in the literature and/or by manufacturers for the lesion activity assessment (LAA): systems based on visual and tactile criteria, devices based on pH assessment or on optics/light such as the Soprolife® camera.
This present study aims to investigate, ex-vivo, the validity of the Soprolife® camera (sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and positive log-likelihood (PLL)) for LAA in reference to Nyvad criteria as Gold Standard.
A total of 121 permanent molars was included. Within the 48 hours after extraction: 1) two trained senor investigators allocated a Nyvad score to each of the 121 occlusal surfaces (consensus was reached in case of disagreement); 2) pictures of the 121 occlusal surfaces were captured using the Soprolife® camera (detection mode). The pictures were shown to 3 examiners who are graduated dentists and who were previously shown the Soprolife® manufacturer recommendations for LAA (active/inactive according to the fluorescence). The 3 examiners were asked to record independently the activity status of each of the 121 occlusal surfaces. Calculations were done using Stata®.
Results: Se was 60.9% [95% CI: 53.7 to 67.9%]; Sp was 73.1% [95% CI: 65.8 to 79.6%]; PPV was 71.8% [95% CI: 64.2 to 78.5%]; NPV was 62.5% [95 % CI: 55.4 to 69.2%] and PLL was 2.3 [95% CI: 1.7 to 3.0].
Conclusions: The present survey, the first of its kind, showed that Soprolife® camera is a promising tool in term of LAA in clinical practice. Nevertheless, further investigations are needed to validate its use.
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE